Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
mtronicWe refer to your Company’s announcement dated 20 November 2020, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:-
The relevant regulatory approvals required to be obtained before Metronic can commence the distributorship under the Finished Product Model and Fill and Distribution Model of MVC’s COVID-19 vaccine in Malaysia and the estimated time-frame for submission of such applications
solution refer to the Company’s announcements dated 19 August 2020, 24 August 2020, 27 August 2020, 2 September 2020, 23 September 2020 and 24 September 2020. The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that our subsidiary, Solution Biologics Sdn Bhd (“SOLBIO”), had on 30 October 2020 received a Letter of Authorisation (“LOA”) from CanSino Biologics Inc. (“CanSino”, SHSE: 688185, HKEX:06185).
CanSino has authorized SOLBIO to develop the business in Philippines,
CanSino has authorized SOLBIO to develop the business in Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos and Brunei (“Territory”), for their Recombinant Novel Coronavirus Vaccine candidate (Ad5-nCoV) composed of an adenovirus type 5 vector (Bulk Product presentation) (“Bulk Product”), by working with the respective local partners, authorities and regulatory bodies in the Territory in order to prepare the market for the Bulk Product, so that the Product can be sold when it is approved.
